Successful Bone Healing of Nonunion After Ulnar Shortening Osteotomy for Smokers Treated With Teriparatide.
Ulnar shortening osteotomy is widely performed as the standard surgical treatment for ulnar impaction syndrome and has a high percentage of success for pain relief. However, delayed union and nonunion of the osteotomy site remain the most concerning complications. In particular, smokers have a higher incidence of nonunion, which amounts to 30% of cases. For the treatment of nonunion, secondary surgical interventions such as bone grafting will be necessary but are extremely challenging. Recently, teriparatide (recombinant human parathyroid hormone [PTH 1-34]) administration has been reported in several clinical studies as a noninvasive pharmacological systemic treatment for fracture healing or nonunion. The authors present 2 cases of smokers, a 62-year-old man and a 42-year-old woman, with nonunion after ulnar shortening osteotomy and fixation with 6-hole non-locking plate for ulnar impaction syndrome. For treatment of nonunion, noninvasive therapy with teriparatide (20-µg, subcutaneous injection) in addition to low-intensity pulsed ultrasound was underwent. In both cases, partial bone union began to be observed on radiographs after the first 4 weeks of teriparatide administration and successful bone healing without additional surgical interventions was achieved after 10 and 6 months of treatment with teriparatide, respectively. The current case reports showed that non-invasive combination therapy of teriparatide and low-intensity pulsed ultrasound were a possible alternative to surgical intervention. In the future, teriparatide therapy might be applied actively to patients who have risk factors for delayed union, such a heavy smoking habit, and are expected to experience nonunion after ulnar shortening osteotomy.
Takuya
T
Uemura
Mitsuhiro
M
Okada
Takuya
T
Yokoi
Kosuke
K
Shintani
Hiroaki
H
Nakamura
D000328:Adult; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001860:Bone Plates; D003131:Combined Modality Therapy; D005260:Female; D017102:Fracture Healing / Q000187:drug effects*; D005599:Fractures, Ununited / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010027:Osteotomy / Q000379:methods*; D012907:Smoking / Q000009:adverse effects* / Q000503:physiopathology; D013580:Synostosis / Q000628:therapy; D019379:Teriparatide / Q000627:therapeutic use*; D014457:Ulna / Q000601:surgery; D014464:Ultrasonic Therapy / Q000379:methods
D050071:Bone Density Conservation Agents; D019379:Teriparatide